INOVIO Pharmaceuticals
NEWS ALERT

FDA Accepts for Review INOVIO’s BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)

Press Releases

Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO’s Partner in China

Posted on May 21, 2026

Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO’s Partner in China

Posted on May 21, 2026

INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights

Posted on May 13, 2026

INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights

Posted on May 13, 2026

INOVIO to Participate in Upcoming Scientific Conferences

Posted on May 8, 2026

INOVIO to Participate in Upcoming Scientific Conferences

Posted on May 8, 2026

INOVIO to Report First Quarter Financial Results on May 13, 2026

Posted on May 1, 2026

INOVIO to Report First Quarter Financial Results on May 13, 2026

Posted on May 1, 2026

INOVIO Announces Pricing of $17.5 Million Public Offering

Posted on April 16, 2026

© Copyright 2026 INOVIO Pharmaceuticals. All rights reserved.